Genetically Modified Food and International Law - The Biosafety Protocol and Regulations in Europe by Nanda, Ved P.
Denver Journal of International Law & Policy 
Volume 28 
Number 3 Summer - 1999 Sutton Colloquium & 
McDougal Lecture 
Article 2 
May 2020 
Genetically Modified Food and International Law - The Biosafety 
Protocol and Regulations in Europe 
Ved P. Nanda 
Follow this and additional works at: https://digitalcommons.du.edu/djilp 
Recommended Citation 
Ved P. Nanda, Genetically Modified Food and International Law - The Biosafety Protocol and Regulations 
in Europe, 28 Denv. J. Int'l L. & Pol'y 235 (2000). 
This Article is brought to you for free and open access by Digital Commons @ DU. It has been accepted for 
inclusion in Denver Journal of International Law & Policy by an authorized editor of Digital Commons @ DU. For 
more information, please contact jennifer.cox@du.edu,dig-commons@du.edu. 
GENETICALLY MODIFIED FOOD AND
INTERNATIONAL LAW -
THE BIOSAFETY PROTOCOL AND
REGULATIONS IN EUROPE*
VED P. NANDA*
I. INTRODUCTION
Biotechnology has the potential to transform industry, including
pharmaceuticals, and agriculture.! The Biosafety Protocol [hereinafter
Protocol], adopted by over 130 states in Montreal, Canada, on January
30, 2000, defines modern biotechnology in the context of regulating the
international trade of genetically modified organisms (GMOs). This
regulation takes place through the application of "(a) In vitro nucleic
acid techniques, including recombinant deoxyribonucleic acid (DNA)
and direct injection of nucleic acid into cells or organelles, or (b) Fusion
of cells beyond the taxonomic family, that overcome natural physiologi-
cal reproductive or recombination barriers and that are not techniques
used in traditional breeding and selection."' The Protocol defines a liv-
ing organism as "any biological entity capable of transferring or repli-
cating genetic material, including sterile organisms, viruses and vi-
* This is an adapted version of my presentation at a panel entitled, "Genetically Modified
Food: Friend or Foe," which I chaired, at the International Law Weekend of the American
Branch of the International Law Association at New York, on November 6, 1999. I am
grateful to Martha Keister, the International, Comparative and Foreign Law Librarian at
the University of Denver College of Law, and William Goldstein, General Counsel, Ma-
harishi University of Management, Fairfield, Iowa, for their invaluable help in obtaining
several documents from international governmental and nongovernmental organizations.
Editor's Comment: This article has not been revised since summer 1999.
"" Vice Provost, University of Denver; Thompson G. Marsh Professor of Law and Director
of the International Legal Studies Program, University of Denver, College of Law.
1. In 1987, the National Academy of Sciences released its study regarding the poten-
tial of biotechnology. NAS, INTRODUCTION OF RECOMBINANT DNA-ENGINEERED
ORGANISMS INTO THE ENVIRONMENT: KEY ISSUES (1987). See also U.S. CONGRESS,
OFFICE OF TECHNOLOGY ASSESSMENT, BIOTECHNOLOGY IN A GLOBAL ECONOMY (1991).
2. Convention on Biological Diversity, Report of the Extraordinary Meeting of the
Conference of the Parties for the Adoption of the Protocol on Biosafety to the Convention on
Biological Diversity, UNEP, Pt. Two, Annex to decision EM-I13: Cartagena Protocol on
Biosafety to the Convention on Biological Diversity, art. 3(i), U.N. Doc.
UNEP/CBD/ExCOP/1/3 (2000) [hereinafter Biosafety Protocol].
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roids."3 It defines a living modified organism as "any living organism
that possesses a novel combination of genetic material obtained through
the use of modem biotechnology."4 Thus, a GMO or transgenic product
is created by inserting foreign genes from one organism into another,
thereby crossing species barriers. Thus, genes from viruses, bacteria
and animals may be planted in grains, fruits and vegetables.
Genetic modification (GM) or manipulation in agriculture, under-
taken by what is commonly known as genetic engineering, is aimed at
increasing the quantity of world food supplies and improving their qual-
ity by enhancing beneficial traits, such as making crops resistant to in-
sects or herbicides and reducing their dependence on pesticides. Two
examples are insect-resistant corn and Roundup-Ready soybeans, which
are impervious to Roundup herbicide, manufactured by the giant bio-
tech firm Monsanto, the largest producer of GM seeds. Major substan-
tive issues related to the creation and use of and trade in GMO products
include the threat to biological diversity, economic considerations, intel-
lectual property issues, ethical and religious concerns, risks to human
and animal life or health, consumers' right to know, and food security.5
The security interest, may be affected in several says, such as further
consolidation of control over the methods of food production in the
hands of a few large firms, excessive use of chemicals because of the in-
creasing resistance of crops to herbicides, and reductions in crop diver-
sity.
6
While all these issues are important, in this paper I will focus the
discussion primarily on 1) the attempts internationally to regulate the
trade in GMOs by the adoption of the Biosafety Protocol, and 2) regula-
tion of GMOs in Europe. The first section will briefly describe the con-
troversy. The second section will discuss the regulatory practice in the
United States. The third and fourth sections will describe and analyze
the Biosafety protocol and GMOs' regulation in Europe, respectively,
before the final concluding section.
II. THE CONTROVERSY
The use of biotechnology in agricultural practices has increased
substantially in the United States and other major food exporting coun-
tries. These exporters are also the foremost proponents of the biotech-
3. Id. at art. 3(h).
4. Id. at art. 3(g).
5. See Center for International Environmental Law, Implications of Proposals to
Consider Trade in Genetically Modified Organisms (GMOs) at WTO-Draft Discussion
Paper 1-2 (Oct. 1999) (copy on file with the Denver Journal of International Law and Pol-
icy).
6. See id.
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nology industry and operate as the so-called "Miami Group"7 . To illus-
trate, 50 percent of soybean and one-third of corn crops in the United
States in 1999 were grown from GM seed, and almost all canola oil in
the US is made from genetically altered rape seeds.8 Similarly, in Ar-
gentina, the world's largest soybean exporter, GM soybeans accounted
for approximately 70 percent of the 1998-99 soybean crop.9
The controversy surrounds the genetically modified crops because
of the potential long-term risks to human health and the environment
caused by the release of GMOs into the environment. Proponents claim
that GM foods are beneficial because of their higher nutrient value and
because of their capacity to substantially increase food production to
feed the world's growing population. On the other hand, critics argue
that the potential risks cannot be dismissed. Among unanticipated out-
comes, the new genes might jump to other crops or species, or even to
people. For example, unexpected toxins or allergens may be introduced
into crops through genetic engineering, thus causing unforeseen allergic
reactions in humans. In 1996, scientists genetically engineered soy-
beans to incorporate a gene from Brazil nuts that enhanced the soy-
beans' protein content. Subsequent testing showed that the protein in-
troduced could trigger allergic reactions similar to those caused by
Brazil nuts." A plant with genes resistant to insects or herbicides could
spread that gene through pollination, thus creating "super weeds.""
Recent laboratory studies have shown that the pollen of genetically al-
tered corn can kill caterpillars of the monarch butterfly, that the lives of
ladybirds are shortened when they are fed aphids living on GM crops,
and that lacewings, natural predators of insect pests, are killed when
they are fed corn borer worms raised on genetically altered corn
plants.'"
Consumer resistance to GM foods in Europe has been intense.
United States exports to Europe of corn and soybeans, both genetically
modified and conventional, have declined from nearly $3 billion in 1996,
7. The Miami group, consisting of Argentina, Australia, Canada, Chile and Uru-
guay, was named after the city where the group first met to promote free trade in GMs
8. See Ruth Walker, Safety Rules for Genes and Food, CHRISTIAN SCI. MONITOR,
Jan. 25, 2000, at 1. Andrew Pollack, 130 Nations Agree on Safety Rules for Biotech Food,
N.Y. TIMES, Jan. 30, 2000, at Al.
9. See Ben Christie, Tweaked Beans Do Not Faze the Farmers of Argentina, FIN.
TIMES, Feb. 11, 2000, at 34.
10. See Peter N. Spotts, The Brave New World of Biotechnology and Beyond,
CHRISTIAN SCI. MONITOR, Oct. 28, 1999, at 17.
11. See David Nicholson-Lord, GM Foods: The Natural Result of Genetic Change,
INDEPENDENT (London), Oct. 12, 1999, features section; Andrew Pollack, We Can Engi-
neer Nature. But Should We?, N.Y. TIMES, Feb. 6, 2000, at 16.
12. See Robert C. Cowen, New Findings Say Genetically Altered Corn Can Poison the
Soil, CHRISTIAN SCL MONITOR, Dec. 2, 1999, at 2; Paul Brown, From Gung-ho to Accep-
tance of Legitimate Concerns, GUARDIAN (London), Feb. 28, 2000, at 6.
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when American farms began shipping biotechnology crops to Europe, to
about $1 billion in 1999.13 While European regulators have not ap-
proved any new GM seed strains for nearly two years, "[pilanting, im-
porting or selling genetically altered seeds or foods has virtually
stopped, because farmers will not plant the seeds, consumers will not
buy the foods, and stores decline to stock them."14
A major controversy was sparked when scientist Arpad Pusztai, at
Rowett Research Institute in Aberdeen, Scotland, reported on British
television that transgenic potatoes damaged the health of rats by stunt-
ing their growth and injuring their immune systems. 5 He was fired
and silenced. Subsequently, however, the British medical journal, The
Lancet, published a peer-reviewed paper co-authored by Pusztai in
which he repeated the finding. 6 According to polls, only one percent of
Britons think that there is any value in GM plants, and ingredients
from these plants are called "Frankenstein food" by several British
newspapers. 7 It is ironic that at a kitchen at Monsanto's Britain fac-
tory only GM-free meals are served. 8 Bowing to consumer concern,
British Prime Minister Tony Blair wrote in late February 2000:
There is no doubt that there is potential for harm, both in terms of
human safety and in the diversity of our environment, from GM foods
and crops. It's why the protection of the public and the environment is,
and will remain the Government's over-riding priority.
Testing [of GM food ingredients] has been tightened by this govern-
ment even further. I can promise that no GM food will be put on the
market here without going through the most rigorous safety assess-
ments in the world.
We also recognize the genuine fears over the impact of GM crops on
13. See David Barboza, In the Heartland, Genetic Promises, N.Y. TIMES, Mar. 17,
2000, at C6.
14. Donald G. McNeil, Jr., Protests on New Genes and Seeds Grow More Passionate in
Europe, N.Y. TIMES, Mar. 14, 2000, at Al.
15. For a short report, see Joel Bleifuss, No Small (Genetic) Potatoes; A British Re-
searcher Raises Doubts About Genetically Engineered Food, IN THESE TIMES, Jan. 10,
2000, at 2.
16. See id. See also Geoffrey Lean, Exposed: Blair's Hypocrisy Over GM,
INDEPENDENT (London), Mar. 5, 2000, at 13 ("The [British] Government has also refused
to repeat research by Dr. Arpad Pusztai, which suggested that eating GM potatoes dam-
aged the health of rats, even though it was financed by the official bodies in the first
place.")
17. See McNeil. Jr., supra note 14; Warren Hoge, Britons Skirmish Over Genetically
Modified Crops, N.Y. TIMES, Aug. 23, 1999, at A3. "A new MORI poll says 79 percent of
the British public think that genetically modified crop testing.., should be stopped. Ma-
jor food manufacturers, supermarkets and fast food chains have already announced the
removal of all genetically modified ingredients from their products sold in Britain." Id.
18. See Michael Mccarthy, GM Food Banned in Monsanto Canteen, INDEPENDENT
(London), Dec. 22, 1999, at 7.
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our environment and wildlife. That is why no GM crops will be grown
commercially in this country until we are satisfied there will be no un-
acceptable impact on the environment.
We have insisted that products containing GM foods on shop shelves
have to be labeled. And anyone eating in a restaurant has a legal right
now to ask whether the food they serve contains GM ingredients. And
we are leading the fight to have labeling extended in Europe. ' 9
The Minister for the Cabinet Office in Britain, Mo Mowlam, had
earlier said in December 1999 that in 2000, the government would an-
nounce new rules on labeling of additives and flavorings as well.2 0 In
Wales, there has been a movement toward declaring that region of
Britain a GM-free zone.2 ' Because of the backlash against GM crops,
the biotechnology industry is unable to find enough British farmers
willing to grow GM crops even for a trial period. 2
The concern has now spread beyond Europe to many other coun-
tries. For example, the Washington Post reported in January 2000 that
in Japan,
[i]n the five months since the labeling requirement was announced, a
major supermarket chain has started identifying its genetically modi-
fied products. The Asahi and Kirin Beer Companies said they will
switch entirely to non-genetically modified ingredients. And Japanese
soybean farmers, who do not use any genetically modified seeds, are
enjoying a huge demand for their beans--even at three to four times
the price of imported American ones.2
In Canada, McCain Foods, Ltd., a major potato producer and a
leading supplier of French fries to Burger King, says that it will not use
gene-altered potatoes. ' Similar developments have occurred in several
other countries, including Brazil, 5 Mexico2 and South Korea.
19. Tony Blair, The Key to GM is Its Potential, Both for Harm and Good,
INDEPENDENT (London), Feb. 27, 2000, at 28.
20. See Martha Linden, Mowlam Promises Tougher GM Rules, INDEPENDENT (Lon-
don), Dec. 18, 1999, at 11.
21. Fran Abrams, Wales Set to Throw GM Policy Into Chaos, INDEPENDENT (London),
Mar. 13, 2000, at 5.
22. See Paul Brown, et al., U-Turn By Blair on GM Food, GUARDIAN (London), Feb.
28, 2000, at 1.
23. Kathryn Tolbert, In Japan, It's Back to Nature; Consumers Add Non-Modified
Products to Shopping Carts, WASH. POST, Jan. 24, 2000, at A8. See also Takehiko No-
mura, Japanese Press For Labels on Their Tempered Tofu, CHRISTIAN SCI. MONITOR, Aug.
25, 1999, at 7; Melody Petersen, New Trade Threat for U.S. Farmers, N.Y. TIMES, Aug. 29,
1999, §1, at 1.
24. See Barboza, supra note 13, at C6.
25. See Jack Epstein, Brazilians Boil Over Ban on Altered Beans, CHRISTIAN SCI.
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A major controversial issue is whether genetically modified foods
are "substantially equivalent" to their natural counterparts. The con-
cept of "substantial equivalence" is the basis for US regulators not to
treat such food differently from conventional food. Critics, however, ar-
gue that a GM food's being chemically similar to a conventional food "is
not adequate evidence that it is safe for human consumption."2 They
contend that, while this "approach might seem plausible and attrac-
tively simple... it is misguided, and should be abandoned in favor of
one that includes biological, toxicological and immunological tests
rather than merely chemical ones."29
The concept of substantial equivalence has never been properly de-
fined; the degree of difference between a natural food and its GM alter-
native before its "substance" ceases to be acceptably "equivalent" is not
defined anywhere, nor has an exact definition been agreed by legisla-
tors. It is exactly this vagueness that makes the concept useful to in-
dustry but unacceptable to the consumer. Moreover, "the reliance by
policymakers on the concept of substantial equivalence acts as a barrier
to further research into the possible risks of eating GM foods."30
At an international conference on genetically modified crops in late
February 2000, held in Edinburgh, Scotland, under sponsorship of the
Organisation for Economic Co-operation and Development and funded
by the British government, there was a clash of views on the safety of
GM foods.31 At the conference the assumption of "substantial equiva-
lence," as employed by the US Food and Drug Administration (FDA) in
testing GM foods and thus allowing speedy commercialization of GM
crops throughout the United States, was challenged by an FDA scien-
tist, Dr. Linda Kahl. In a memo, she said, "The process[es] of genetic
engineering and traditional breeding are different, and according to the
technical experts in the [FDA], they lead to different risks."32
The concern with potential risks of GM foods has spread to the
United States, as well. Some food and beverage companies and several
grocery chains have decided not to carry GM foods. To illustrate, Ger-
ber and Heinz baby foods have announced that they will not use geneti-
MONITOR, Aug. 25, 1999, at 1 (In June 1999, a federal judge banned sales of Monsanto's
Roundup Ready soybean seeds until the government sets biosafety rules). Australia and
Singapore have also begun regulating GMOs. See Id.
26. See Petersen, supra note 23, at 1.
27. Id.
28. Erik Millstone, Eric Brunner & Sue Mayer, Beyond 'Substantial Equivalence,' 401
NATURE 525 (Oct. 7, 1999).
29. Id.
30. Id.
31. See Michela Wrong, Differences Widen on Use of Modified Foods, FIN. TIMES
(London), Feb. 29, 2000, at 14.
32. Quoted in Jack O'Sullivan, US "Covered Up Warnings from Its Scientists on Dan-
gers of GM Foods," INDEPENDENT (London), Feb. 29, 2000, at 2.
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cally altered corn or soy ingredients because of public concern about
safety.' In January 2000, Frito-Lay, Inc., told the farmers who grow
the corn used in its snack foods not to use genetically engineered seed
for this year's planting.' Whole Foods Markets, a chain of 104 natural
foods supermarkets, has committed itself to not using GM ingredients
in its Whole Foods brand or private label products.35 Over 30 farm
groups across the country have warned their members that planting
GM crops might be risky to their livelihoods because of the unpopular-
ity of such crops with consumers, and because farmers could be vulner-
able to "massive liability" from damage caused by the spread of biologi-
cally modified pollens.36 A study by the American Corn Growers
Association published in February, 2000, showed a sixteen percent drop
in sowings of GM maize across the US Midwest. 7
The battle against GM crops has, however, apparently led Mon-
santo to renounce the use of "terminator" genes in their plants, by
which the next generation of seeds is rendered infertile, thus preventing
farmers from saving seeds from year to year.38 In mid-December 1999,
several plaintiffs, five farmers in the US and one in France, filed a
class-action lawsuit in US district court in Washington against Mon-
santo.39 They alleged fraud and violations of US anti-trust laws, claim-
ing that the defendant had: (1) defrauded them by telling them that GM
33. See Alex Salkever, Are These New Bio-Crops Safe?, CHRISTIAN SCI. MONITOR,
Aug. 5, 1999, at 3; Laurent Belsie, New Genes Meet a Wary Market, CHRISTIAN SCI.
MONITOR, Dec. 8, 1999, at 1; Eating Well: What Labels Don't Tell You (Yet), N.Y. TIMES,
Feb. 9, 2000, at 5 [hereinafter Eating Well]. A leading brand of baby food, Earth's Best, a
division of the Hain Food Group, also announced in January 2000 that it would not use
GM ingredients. See Florence Fabricant, Food Stuff, N.Y. TIMES, Jan. 26, 2000, at F2.
See also David Barboza, Modified Foods Put Companies in a Quandry, N.Y. Times, Jun. 4,
2000, sec. 1, at 1.
34. See Eating Well, supra note 33.
35. Id.
36. See William Claiborne, Biotech Crops Spur Warning; 30 Farm Groups Say Con-
sumer Backlash Could Cost Markets, WASH. POST, Nov. 24, 1999, at All.
37. See Michela Wrong, Modified Crop Sowings to Fall, FIN. TIMES (London), Feb. 23,
2000, at 6 (In late March 2000, the U.S. Department of Agriculture released a survey
showing that "biotech corn planting could be down 24 percent from a year ago and soya-
beans could be down 9 percent); David Barboza, Farmers are Scaling Back Genetically
Altered Crops, N.Y TIMES, Apr. 1, 2000, at 5.
38. See generally James Erlichman, GM Foods: Fighting for the Future of Our Food,
INDEPENDENT (London), Oct. 12, 1999, from Features section; John Vidal, The Seeds of
Wrath; Thousands Will Demonstrate Today at a Meeting of the Leading Economic Powers,
GUARDIAN (London), Weekend Page, June 19, 1999, at 10; Ending a Genetic Food Fight,
Editorial, CHRISTIAN SCI. MONITOR, Sept. 28, 1999, at 20.
39. See John Schwartz, 6 Farmers in Class Action vs. Monsanto; Lawsuit Questions
the Company's Testing of Genetically Modified Seeds, WASH. POST, Dec. 15, 1999, at El;
Henry Miller, The Unexpected Arm of the Bio-Police, FIN. TIMES (London), Dec. 21, 1999,
at 10; Scott Kilman, Monsanto is Sued Over Genetically Altered Crops, WALL. ST. J., Dec.
15, 1999, at A3.
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seeds were safe and that the public would accept GM crops, because the
company should have known that adequate standards of testing do not
exist in any state and hence such safety could not be assured; and had
(2) conspired to monopolize the world's market for GM agriculture by
patenting genes and requiring that farmers "license" their seeds instead
of buying them outright. Earlier, in May 1998, the Alliance for Bio-
Integrity filed a lawsuit against the FDA seeking mandatory safety
testing and labeling of all GM foods. The plaintiff alleged that current
FDA policy, under which GM foods are authorized to be marketed with-
out testing and labels, violates the Agency's statutory mandate to pro-
tect public health and to provide consumers with relevant information
about the foods they eat.40
Finally, shareholders of several corporations have called for share-
holder votes to halt the development and sale of GM food and crops un-
til they are tested on a long-term basis and are shown to be safe to both
humans and the environment.41
40. Alliance for Bio-Integrity, Landmark Lawsuit Challenges FDA Policy on Geneti-
cally Engineered Food, Press Rel., (visited 3/27/00) <http://www.biointegrity.org> (copy on
file with the Denver Journal of International Law and Policy). See also Alliance for Bio-
Integrity, Statement of Steven M. Druker, Lawsuit Uncovers Disagreement Within FDA
Over Safety of Biotech Foods (visited March 27, 2000) <http://www.biointegrit.or>:
The FDA's records reveal it declared genetically engineered foods to be safe
in the face of broad disagreement from its own experts-all the while claim-
ing a broad scientific consensus supported its stance. Internal reports and
memoranda disclose: (1) agency scientists repeatedly cautioned that foods
produced through recombinant DNA technology entail different risks than do
their conventionally produced counterparts and (2) that this input was con-
sistently disregarded by the bureaucrats who crafted the agency's current
policy, which treats bioengineered foods the same as natural ones.
Id. In October 2000, a federal judge upheld the Food and Drug Administration's policy on
genetically modified food, dismissing the lawsuit, stating that the government did not
have to follow procedures for public notice and comment or file an environmental impact
statement because there has been no formal regulation announced by the agency. See
Andrew Pollack, Judge Upholds F.D.A. Policy on Genetically Altered Foods, N.Y. Times,
Oct. 4, 2000, at C18.
41. See Mary Dejevsky, Big US Firms Face Investors' Revolt Over GM Foods,
INDEPENDENT (London), Feb. 15, 2000, at 13.
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III. THE U.S. REGULATORY FRAMEWORK42
A. Introduction
The United States has no special laws that specifically apply to GM
foods. The biotech approval process involves three departments: the US
Department of Agriculture (USDA), the Environmental Protection
Agency (EPA), and the Food and Drug Administration (FDA). However,
biotech companies are only required to consult the FDA as they bring
new biotech products to market, so long as the added genes do not sub-
stantially change the nature of the foods. Labeling is also not required.
Environmental groups and consumer activists demand that extraordi-
nary steps be taken to ensure the safety of GM food, since the technol-
ogy is totally novel and is practically transforming our food supplies.
Unlike several states that apply process-oriented approaches,
thereby implementing new biotechnology laws to regulate GMO re-
leases,43 the US regulates GMOs under already-existing statutes. For a
decade since the mid-1970s, the National Institute of Health (NIH) was
primarily responsible to ensure genetic engineering safety and hence
established guidelines for research involving recombinant DNA in
1976." Subsequently, in 1986, the Coordinated Framework for Regula-
tion of Biotechnology was issued by the Office of Science Technology
Policy,45 prescribing jurisdiction over biotechnology regulation among
several federal agencies. Under the Framework several general princi-
ples apply: (1) existing laws are to regulate biotechnology;46 (2) the
products of biotechnology and not the process are to be regulated; 7 (3)
the safety of a biotechnology product is to be determined on a case-by-
case basis;4" and (4) a coordinated effort is to be undertaken between all
the agencies involved in regulating biotechnology.
49
The following discussion will address the roles of major agencies in-
42. For a thorough review, see T. Morath, Office of U.S. Trade Representative, U.S.
Regulation of Products Derived from Biotechnology (1998) [hereinafter Morath]. See also
Terence P. Stewart & David S. Johanson, Policy In Flux: The European Union's Laws on
Agricultural Biotechnology and Their Effects on International Trade, 4 DRAKE J. AGRIC. L.
243, 248-52 (1999); Judy J. Kim, Out of the Lab and Into the Field: Harmonization of De-
liberate Release Regulations for Genetically Modified Organisms, 16 FORDHAM INT'L L. J.
1160 (1993).
43. See Kim, supra note 42, at 1169-77.
44. For a discussion of NIH's role, see id. at 1178-79.
45. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23, 302
(1986).
46. Id.
47. Id.
48. Id.
49. Id.
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cluding the EPA, USDA and FDA in regulating biotechnology. The sec-
tion will conclude with a case holding that a mandatory law may be un-
constitutional.
B. The Environmental Protection Agency
The current procedure calls for the EPA to approve pesticides de-
rived from biotechnology and bioengineered plants that contain Bacillus
thuringiensis ("Bt"), which is toxic to certain maize pests.50 Two stat-
utes are applicable to regulating the release of GMOs-the Federal In-
secticide, Fungicide and Rodenticide Act (FIFRA)5" and the Federal
Food, Drug and Cosmetic Act (FFDCA).52 Under the former, a manufac-
turer is required to register a pesticide, including plants with pesticidal
qualities, with the EPA before selling it in the US market.53 The EPA
performs two main regulatory functions. First it establishes maximum
tolerance levels for pesticide residues in foods. Second, before new mi-
croorganisms, which include intergeneric organisms derived through
biotechnology, can be manufactured or imported, the EPA must be noti-
fied in accordance with the Toxic Substances Control Act.5
Because of the rising concern over the safety of biotech crops, the
EPA responded to the Cornell laboratory study showing that GM pollen
could kill monarch butterfly caterpillars by announcing new regulations
to take effect in the spring of 2000. These new regulations, inter alia,
ask farmers "to voluntarily protect butterflies by planting traditional
corn around the edges of Bt corn fields. That would create a buffer to
prevent toxic pollen from blowing into butterfly habitats."55 It also re-
quired farmers to plant at least 20 percent of their crops as non-Bt corn.
The purpose of this requirement is to slow the evolution of resistance to
the Bt toxin, a natural insecticide available to organic farmers."'
C. The U.S. Department of Agriculture
The USDA's regulation of the release of GMOs is done under its
50. See Morath, supra note 42, at 1; Novartis Seeds-Approval of a Pesticide Product
Registration, 63 Fed. Reg. 43,935, 43,935 (1999).
51. 7 U.S.C. §§1 3 6-13 6y.
52. 21 U.S.C. §§301-395.
53. See Morath, supra note 42, at 1. According to a draft notice published August 9,
2000 (65 Fed. Reg. 48,701(2000)), the EPA is expected to issue a final rule classifying the
agency's procedure of regulating genetically engineered plant pesticides while exempting
from federal oversight traditional plant breeding. EPA to Make Final "Core Components"
of Regulation Covering Transgenic Plants, 23 Int'l Env. Rep. (BNA), Curr. Rep., Aug. 16,
2000, at 644.
54. 15 U.S.C. §2603(d).
55. Carol Kaesuk Yoon, E.P.A. Announces New Rules on Genetically Altered Corn,
N.Y. TIMEs, Jan. 17, 2000, at A13.
56. See id.
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Animal Plant and Health Inspection Service (APHIS), insofar as the
GMOs are genetically engineered microorganisms derived from plant
pests." Those developing a new GMO plant must submit a petition to
APHIS showing that, based upon field trials, the plant is safe and poses
no risks as a plant pest. 8 APHIS's task is to conduct an environmental
assessment to determine the GMO's possible effects on human health
and the environment.59
APHIS will issue a "determination of non-regulated status" if it
finds that the GMO is not a plant pest.60 Then, the GMO may be re-
leased into the environment, that is, planted. From 1992 to 1998
APHIS provided non-regulated status to 36 genetically modified
plants. 1
In March 2000, the Department of Agriculture proposed strict rules
prohibiting the use of GM ingredients in products carrying the organic
label. The new rules, which could take effect by the end of 2000, ad-
dress concerns about the use of three processes, genetic engineering,
sewage sludge, and irradiation, in the production of food products that
", 62
are labeled "organic. This revision of the 1995 USDA rules would
have established a nationwide certification program for organic foods.
Presently, in order for raw products to be considered one hundred per-
cent organic, "they must be grown or manufactured without added hor-
mones, pesticides or synthetic fertilizers.'
D. The Food and Drug Administration
The Federal Food, Drug, and Cosmetic Act authorizes the FDA to
ensure the safety of most foods, which includes foods derived through
biotechnology. ' It requires that new additives in food be demonstrated
safe through standard scientific testing prior to their marketing.6
However, biotech companies producing GM foods need not obtain ap-
57. See Morath, supra note 42, at 1 (APHIS' authority is under Federal Plant Pest
Act (7 U.S.C. §§150aa-150jj) and the Plant Quarantine Act (7 U.S.C. §§151-167)).
58. See Morath, supra note 42, at 5.
59. See id. at 4.
60. See id. at 1.
61. Animal and Plant Health Inspection Service, U.S.D.A., Crop Lines No Longer
Regulated by USDA, (visited March 27, 2000) <http:/ www.aphis.usda.dov/biotech/not
reg.html>, cited in Stewart & Johanson, supra note 42, at 250 n.38.
62. See New Rules on Organic Foods, N.Y. TIMES, Mar. 9, 2000, at A28.
63. Id. See also Strict Rules to Limit Genetic Engineering on Organic Foods, N.Y.
TIMES, Mar. 5, 2000, at 1 ("The [new rules] indicate an about-face in the agency's attitude
on organic farming and represent one of several steps it is taking to help small and me-
dium-sized farmers, who have received comparatively little attention from the agency for
decades.")
64. 21 U.S.C. §§301-395.
65. See id. §321.
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proval from the FDA to introduce such foods into the US market, and
no prior testing is required, as the FDA considers them sufficiently
similar to conventional foods, and they are thus "generally recognized
as safe." Hence, the FDA does not regulate GMOs differently than their
conventional counterparts. However, companies do usually consult the
FDA before marketing their products, and the FDA has issued guide-
lines to assist the companies in this regard." If it is discovered through
consultations that a new product raises health concerns, the FDA may
require under the FFDCA that a pre-market review be performed.67
Those introducing the food product into the market are under a legal
obligation to ensure that the food is safe.' Thus the responsibility for
ensuring food safety is on the producer, who could be criminally liable
for introducing an unsafe food into the marketplace.69 The FDA could
also stop the food's distribution if it is proven unsafe.
Since the US considers GM foods to be substantially equivalent to
those produced through traditional breeding methods,"0 no labeling is
required for GM foods. There could be exceptions, however, when a GM
food product has a significantly different nutritional content or if it
might pose a health risk.7 One example would be where a GM food
product contained a protein derived from a peanut, in which event the
FDA might require labeling to warn consumers who are allergic to pea-
nuts that the product contains such proteins.7'
On the subject of GMO food safety, however, in late 1999, the FDA
decided to hold public meetings. At the first, hearing held in November
1999, both proponents and opponents were vocal in advocating their re-
spective positions,7' the former claiming that the FDA had done an ex-
emplary job in approving GM food and crops in the US as safe, and the
latter arguing that the release of GMOs into the environment poses
risks that are "potentially irreversible, untraceable and uncontrolla-
ble."74 Also in November, Rep. Dennis Kucinich and several co-sponsors
introduced a bill in the U.S. House, the "Genetically Engineered Food
Right to Know Act," specifically citing as one of its threshold findings
that "Federal agencies have failed to uphold Congressional intent by al-
lowing genetically engineered foods to be marketed, sold and otherwise
66. See Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. Reg.
22,984, 22,984.
67. Id. at 22,987-22,989.
68. Id. at 22,988.
69. Id.
70. See id. at 22,991.
71. Id.
72. Id.
73. See generally David Barboza, 2 Sides Square Off on Genetically Altered Food, N.Y.
TIMES, Nov. 19, 1999, at A30.
74. Id.
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used without labeling that reveals material facts to the public."75 Sen.
Barbara Boxer introduced the Senate version in February 2000,76 and
Rep. Kucinich introduced a new House bill, the "Genetically Engineered
Food Safety Act."77 This new piece of legislation refers to the failure of
federal agencies to uphold congressional intent of the Food Additives
Amendment of 1958 by allowing genetically engineered foods to be
marketed, sold and otherwise used without requiring pre-market safety
testing addressing their unique characteristics."8
In some states, such as Colorado and Oregon, citizens' initiatives for
state laws on the subject of mandatory labeling have been undertaken.
On May 3, 2000, the FDA announced that it would strengthen its poli-
cies regarding GM foods and would develop guidelines for companies
that want to label such foods." Biotech companies will henceforth be
required to give a four-month advance notice to the FDA before market-
ing new GM food, providing the agency and the public with the research
finding ensuring the new food's safety.80 Food producers could now vol-
untarily label food as free of gene-altered ingredients."
In the Fall of 2000, the FDA confirmed the presence of unapproved ge-
netically engineered corn in some grocery taco shells and announced
plans to begin testing other corn-based products as well for contamina-
tion.82 Aventis CropScience, S.A., the developer of the corn, known as
StarLink, which was approved in 1998 for use as animal feed but not
for human consumption because of concerns that it might cause allergic
reactions, agreed to voluntarily cancel its marketing license "at the
strong urging" of the EPA, according to the agency.83 Kraft Foods was
75. H.R. 3377, 106th Congress, 1st Session, Nov. 16, 1999, Sec. 2, para. (3).
76. S. 2080, 106th Congress, 2d Session, Feb. 22, 2000.
77. H.R. 3883, 106th Congress, 2d Session, Mar. 9, 2000.
78. Id., Sec. 2, para. 7.
79. See Proposed Collection and Comment Request at 65 FED. REG. 25491, May 2,
2000. See also Melody Petersen, U.S. to Keep Closer Watch on Genetically Altered Crops,
N.Y. Times, May 4, 2000, at A23, col. 5.
80. See John Dillin, White House Enters the Biotech Food Fight, Christian Science
Monitor, May 5, 2000, at 1; Rick Weiss, U.S. to Add Oversight on Biotech Food, Wash.
Post, May 3, 2000, at Al.
81. See Weiss, supra, note 75; Andrew Kimbrell, The F.D.A. Chickens Out, N.Y.
Times, May 8, 2000, at A23, col. 2.
82. See generally Nikki Tait, Taco shell recall puts biotech product testing under
strain: Consumers reacted calmly to evidence of an unapproved corn but the episode
raises important questions, Fin. Times (London), Oct. 11, 2000, at 14. See also Marc
Kaufman, FDA Will Widen Probe of Biotech Corn Misuse, Wash. Post, Oct. 3, 2000, at
813.
83. See Andrew Pollack, Aventis Gives Up License to Sell Biotech Corn, N.Y. Times,
Oct. 13, 2000, at C5; Firm Agrees to Withdraw Biotech Corn; EPA Had Sought Removal
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prompted to recall over 2.5 million boxes of shells sold under the "Taco
Bell" brand.'
E. A Vermont Case Holds That a Mandatory Labeling Law May Be
Unconstitutional
In Vermont a group of trade associations challenged the state's
1994 law mandating the labeling of milk and milk products from cattle
treated with recombinant bovine somatotropin (r-BST) a drug produced
through recombinant DNA technology to increase cows' milk produc-
tion. 85 The purpose of the law was to protect the interest of consumers
who have a "right to know" about the foods they consume.8 The FDA
had determined that milk obtained from cows treated with r-BST posed
no threats to human health. The challenge to the law was based on the
rationale that the right of those dairy producers "not to speak," i.e., not
to label, is protected under the First Amendment. The district court
held that Vermont had a substantial interest in informing consumers of
the use of r-BST in dairy products sold in the state." On appeal, the
Second Circuit overturned the lower court, stating that the "dairy
manufacturers' constitutional right not to speak is a serious one" and
that Vermont's law "requires them to speak when they would rather
not."88 It further said that, in a commercial context, "consumer curiosity
alone is not a strong enough state interest to sustain the compulsion of
even an accurate, factual statement,"8 and since Vermont had demon-
strated "no cognizable harms," it held that the statute would likely be
found unconstitutional and remanded the case for injunction.90
IV. THE BIOSAFETY PROTOCOL
A. Events Leading Up To The Biosafety Protocol
After five years of informal discussions and negotiations, represen-
tatives from over 130 states met in Montreal, Canada, from February
24 to 29, 2000, and finalized the Cartagena Protocol on Biosafety to the
from Market After Latest Discovery in Taco Shells, Wash. Post, Oct. 13, 2000, at A13.
84. See Andrew Pollack, Kraft Recalls Taco Shells With Bioengineered Corn, N.Y.
Times, Sept. 23, 2000, at Cl; Barnaby J. Feder, Companies Act to Keep Bioengineered
Corn Out of Food, N.Y. Times, Sept. 27, 2000, at C2; Marc Kaufman, Biotech Corn Fuels a
Recall; Unapproved Variety Used in Taco Shells, Wash. Post, Sept. 23, 2000, at Al.
85. International Dairy Foods Ass'n v. Amestoy, 898 F.Supp. 246 (D. Vt. 1995).
86. Id. at 248-49.
87. Id. at 253-54.
88. International Dairy Foods Ass'n v. Amestoy, 92 F.3d 67, 71-72 (2d Cir. 1996).
89. Id. at 74.
90. Id.
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Convention on Biological Diversity.9' The Protocol is aimed at protect-
ing the environment from the potential risks caused by the transbound-
ary transfer of living modified organisms (LMOs), including GMOs, cre-
ated by modern biotechnology. The Biological Diversity Convention '
and Agenda 21, 9' an Action Plan calling for sustained economic growth
through international cooperation, both adopted at the United Nations
Conference on Environment and Development (UNCED) (the "Earth
Summit") in Rio de Janeiro in June 1992, address safety issues concern-
ing GMOs.
Although there are several related articles in the Biological Diver-
sity Convention, which call for the signatories to either share technolo-
gies or provide remuneration as reparations to a developing country for
genetic materials taken out of such country, the one specifically appli-
cable to safety issues is article 19.95 The debate around article 19 cen-
tered on whether biotechnology as a process should be regulated. The
US objected to the proposed regulation of biotechnology, contending
that as a process it was not a threat to biological diversity. Article
19(4), as a compromise, obligates each party:
directly or by requiring any natural or legal person under its jurisdic-
tion... [to] provide any available information about the use and safety
regulations required by that Contracting Party in handling such organ-
isms, as well as any available information on the potential adverse im-
pact of the specific organisms concerned to the Contracting Party into
which those organisms are to be introduced."
In addition, Article 19(3) calls upon the parties to consider the need
for and modalities of a protocol setting out appropriate procedures. In
particular, advanced informed agreement, in the field of the safe trans-
fer, handling and use of any living modified organism resulting from
biotechnology that may have an adverse effect on the conservation and
sustainable use of biological diversity."
Regarding the introduction of living modified organisms, the Con-
vention obligates each party, as far as possible and appropriate to,
91. Biosafety Protocol, supra note 2.
92. Convention on Biological Diversity, opened for signature June 5, 1992, reprinted
in 31 I.L.M. 818 (1992) [hereinafter Biological Diversity Convention].
93. See Report of the United Nations Conference on Environment and Development,
U.N. Doc. A/CONF. 151/26/Rev.1, at 12 (1993).
94. See, Biological Diversity Convention, supra note 92, arts. 16, 20, 21.
95. See id. art. 19 (paragraphs (1) and (2) address the participation of the developing
countries in biotechnological research and access to such countries "on a fair and equita-
ble basis" to the "benefits arising from biotechnologies based upon genetic resources pro-
vided by" them. These, however, will not be discussed here.
96. See id. art. 19(4).
97. See id. art. 19(3).
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[elstablish or maintain means to regulate, manage or control the risks
associated with the use and release of living modified organisms result-
ing from biotechnology which are likely to have adverse environmental
impacts that could affect the conservation and sustainable use of bio-
logical diversity, taking also into account the risks to human health.98
The United States, however, did not sign the Convention, contend-
ing that the text was "seriously flawed in a number of important as-
pects."" The US found "particularly unsatisfactory the text's treatment
of... technology transfer and bio-technology.""°
Chapter 16 of Agenda 21 entitled "Environmentally Sound Man-
agement of Biotechnology," states that Agenda 21's goal is to foster in-
ternational principles for the environmental management of biotechnol-
ogy and to promote sustainable applications of biotechnology. 10' Among
other chapters, chapter 14 provides for the sharing of research and
plant genetic resources among nations."°' Chapter 15 aims at improving
the conservation of biological diversity and supporting the Biodiversity
Treaty. 3 Finally, Chapter 19 addresses the issue of risk management
of toxic chemicals and may also apply to certain biopesticides and other
hazardous products of biotechnology."
It was pursuant to the Article 19(3) mandate of the Biodiversity
Convention that the discussions on the drafting of a Protocol had begun.
Thus, although between July 1996 and February 1999 the ad hoc work-
ing group on biosafety, established by the parties to the Convention,
had held six meetings,' a final consensus on all points had not been
reached on the draft at the earlier session of the parties, which met in
Cartagena, Colombia, from February 22-24, 1999. Since the Cartagena
session had been convened before the negotiations on the draft text of
the Protocol could be concluded," it ended in an impasse. Several
groups presented proposals at the session, including the European Un-
98. Id. art. 8(g).
99. Declaration of the United States of America, attached to the Nairobi Final Act,
reprinted in 31 I.L.M. 842, 848, para. 3 (1993).
100. Id. para. 4.
101. See Agenda 21, UN Doc. A/CONF.151/26/Rev.1 (Vol. I), ch. 16, at 218 (1993). The
final program areas in biotechnology include establishing enabling mechanisms for the
development of and the environmentally sound application of biotechnology. Id.
102. Id. ch. 14.57(d), at 195: "To take appropriate measures for the fair and equitable
sharing of benefits and results of research and development in plant breeding between
sources and users of plant genetic resources."
103. Id. ch. 15, at 210.
104. Id. ch. 19, at 315.
105. UNEP, Convention on Biological Diversity, Conference of the Parties to the Con-
vention on Biological Diversity, Draft Report of the Extraordinary Meeting of the Confer-
ence of the Parties for the Adoption of the Protocol on Biosafety to the Convention on Bio-
logical Diversity, U.N. Doc. UNEP/CBD/ExCOP/1/L.2/Rev. 1, para. 28, Feb. 23, 1999
[hereinafter Cartagena Report].
106. Id. para. 22.
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ion,'°7 the Miami Group, 10 8 and the third on behalf of the "like-minded
group of countries."'09 The meeting adjourned, deferring the solution for
the next meeting in Montreal. " '
The period between the Cartagena meeting and the resumed ses-
sion in Montreal provided members with an opportunity to continue in-
formal discussions. Although there was concern that the Montreal ne-
gotiations might also collapse, meeting a similar fate as those at
Cartagena, the Montreal session succeeded with the parties reaching an
agreement, to the surprise of many negotiators."' As The Economist
reported, while the Cartagena session had failed because of the opposi-
tion of the Miami Group, "the softening-up process that has occurred
during the past eleven months-the consumer and producer revolt, and
the vacillation about the technology by the purveyors themselves, seems
to have made these countries more amenable to a deal.""'
B. Content and Analysis
The Biosafety Protocol reflects the commitment of the international
community to provide for safety in biotechnology and is, indeed, a his-
toric attempt to reconcile economic and trade policies with environ-
mental concerns. It incorporates the precautionary principle in the
process of decision-making, and underscores the need to enhance the
capacity building of the developing states to ensure biotechnology
safety.
The Protocol establishes that strict "Advanced Informed Agree-
ment" procedures be applied to LMOs, including seeds, plants, live fish
and other organisms, that are to be intentionally introduced into the
environment. The exporter in these cases is required to provide de-
tailed information to each importing country in advance of the first
shipment, and the importer must then authorize the shipment. This
procedure is designed to ensure that recipient countries have both the
opportunity and the capacity to assess risks pertaining to the products
of modern biotechnology.13 However, this procedure does not apply to
the intentional transboundary movement of LMOs if they are "not likely
107. Id. Annex II.
108. Id. Annex III.
109. Id. Annex IV.
110. For the contents of the Draft Protocol on Biosafety, see id. Annex to decision EM-
1/3.
111. See Edward Alden, Greens and Free-Traders Join to Cheer GM Crop Deal, FIN.
TIMES (London), Jan. 31, 2000, at 11; Pollack, supra note 8; John Burgess, Trade Rules
Set on Food Genetics; Compromise Gained on Labeling Issue, WASH. POST, Jan. 30, 2000,
at Al.
112. A Conventional Argument, ECONOMIST, Jan. 29, 2000, at 95.
113. See Biodiversity Protocol, supra note 2, arts. 7-16; 25-26.
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to have adverse effects on the conservation and sustainable use of bio-
logical diversity, taking also into account risks to human health."
14
The Protocol, however, applies to neither pharmaceuticals," 5 nor to
commodities such as soybeans or maize, intended for direct use as food,
feed, or processing. 6 These were among the contentious issues pri-
marily responsible for the failure of the Cartagena meeting to reach an
accord on the Biosafety Protocol. The United States, although not a
party to the Convention on Biological Diversity and hence not an official
participant at the Cartagena and Montreal meetings, expressed its con-
cerns through its allies in the Miami Group, and was the major oppo-
nent of any regulation pertaining to food commodities and pharmaceu-
ticals in the proposed Protocol.
The procedure calls for a party that decides to place on the market
an LMO commodity "that may be subject to a transboundary movement
for direct use as food or feed, or for processing," to inform the parties
through the Biosafety Clearinghouse."' The Biosafety Clearinghouse is
established under the Protocol to:
(a) Facilitate the exchange of scientific, technical, environmental and
legal information on, and experience with, living modified organisms;
and
(b) Assist parties to implement the Protocol, taking into account the
special needs of developing country Parities, in particular the least de-
veloped and small island developing States among them, and countries
with economies in transition as well as countries that are centers of
origin and centers of genetic diversity." s
Another contentious issue on which a compromise was eventually
reached was the labeling of any commodity shipment containing GMOs.
The European Union and developing countries sought provisions for
clear labeling by exporters of any shipment of commodities containing
GMOs. To illustrate, at the Cartagena meeting, the European Union
had submitted its proposal under which an exporter would be required
to clearly indicate as Living Modified Organisms commodities "intended
for direct use as food, feed or processing.""9 The United States and
other exporting countries had claimed that such labeling would be im-
possible for bulk commodity shipments where grain is mixed from many
114. Id. art. 7(4).
115. Id. art. 5: "[Tlhis Protocol shall not apply to the transboundary movement of liv-
ing modified organisms which are pharmaceuticals for humans that are addressed by
other relevant international agreements or organizations."
116. Id. art. 11.
117. Id. art. 11(1); Annex II (information required to be given under article 11).
118. Id. art. 20(1).
119. Cartagena Report, supra note 105, Annex II, para. 2(2)(c).
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different sources.
12 0
As it stands, Article 18, paragraph 2(a) now reads:
Each Party shall take measures to require that documentation accom-
panying:
a) Living modified organisms that are intended for direct use as food or
feed, or for processing, clearly identifies that they "may contain" living
modified organisms and are not intended for intentional introduction
into the environment, as well as a contact point for further informa-
tion. The Conference of the Parties serving as the meeting of the Par-
ties to this Protocol shall take a decision on the detailed requirements
for this purpose, including specification of their identity and any
unique identification, no later than two years after the date of entry
into force of this Protocol.'2'
Thus, there is no specific identification required of the type or na-
ture of GMOs and there is a two- year period following the Protocol's
ratification by fifty states when it will enter into force, 22 before any fur-
ther action can be taken regarding the commodities.
Article 7 of the Protocol exempts "living modified organisms in-
tended for direct use as food or feed, or for processing" from the advance
informed agreement procedure." States are to develop their own na-
tional regimes.
12
Another contentious issue regards the incorporation of the precau-
tionary principle in the Protocol, embodied as Principle 15 of the Rio
Declaration on Environment and Development'2 at the 1992 Earth
Summit. Calling for wide application of the precautionary approach,
the Principle adds that where there is a threat of "serious or irreversi-
ble damage, lack of full certainty shall not be used as a reason for post-
poning cost-effective measures to prevent environmental degrada-
tion."' 26  At Cartagena, the Miami Group took the position that
reference to the precautionary approach in the Protocol must be simply
noted, rather than that the Protocol state in its objective that it is in ac-
cordance with the precautionary approach. 27 In addition, the Group
120. See Alden, supra note 111.
121. Biosafety Protocol, supra note 2, art. 18(2)(a). See also id. paras. 87-88 for a re-
port on the parties' adoption of the above paragraph as an amendment.
122. Id. art. 37.
123. Biosafety Protocol, supra note 2, art. 7(2).
124. See id. arts. 10-16; 25-26.
125. UNCED, Rio Declaration on Environment and Development, U.N. Doc.
A/CONF.151/26/Rev.1 (Vol. I), Annex I, at 3 (1992), reprinted in 31 I.L.M. 874 (1993)
[hereinafter Rio Declaration].
126. See, Rio Declaration, supra note 125, principal 15.
127. Cartagena Report, supra note 105, Annex III, para. 4(a).
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wanted to delete any reference to the precautionary approach from the
decision procedure.12
The Miami Group was unsuccessful in its attempt. The Protocol
reaffirms the precautionary approach in its preamble and retains the
language: "[iun accordance with the precautionary approach contained
in Principle 15 of the Rio Declaration on Environment and Develop-
ment..., the objective of this Protocol is ... ,,129 Furthermore, the lan-
guage contained in the decision procedure is unequivocal:
[1]ack of scientific certainty due to insufficient relevant scientific in-
formation and knowledge regarding the extent of the potential adverse
effects of a living modified organism on the conservation and sustain-
able use of biological diversity in the Party of import, taking also into
account risks to human health, shall not prevent that Party from tak-
ing a decision, as appropriate, with regard to the import of the living
modified organism in question ... in order to avoid or minimize such
potential adverse effects.
30
The same language is also used pertaining to the procedure for LMOs
intended for direct use as food or feed, or for processing.13
Finally, the question of the relationship between the Protocol and
the World Trade Organization (WTO) was resolved by noting in the
preamble that the Protocol would not be subordinate "to other interna-
tional agreements," which in this context, meant primarily the WTO.
The point of contention was that under trade rules it was not the pre-
cautionary approach but certain scientific evidence that would deter-
mine if an importing country could block the shipment of a GMO. To
illustrate the applicable law, the Agreement on the Application of Sani-
tary and Phytosanitary Measures requires that measures that are un-
dertaken by an importing country and designed to protect human, ani-
mal or plant life, must be scientifically supported and verifiable.1 32 It
may be recalled that at the WTO meeting in Seattle in the fall of
1999,1n no decision could be taken about the regulation of biotechnology
under the WTO processes.
The Protocol provides for risk assessment" and risk manage-
ment.13 5 The Biosafety Clearinghouse is designed to assist parties in
128. Id. para. 4(b)
129. Biosafety Protocol, supra note 2, art. 1.
130. Id. art. 10(6).
131. See id. art. 11(8).
132. Agreement on the Application of Sanitary or Phytosanitary Measures, GATT Doc.
M.T.N./FA II-A1A-4, art. 2.2 (Dec. 15, 1993), reprinted in THE RESULTS OF THE URUGUAY
ROUND OF MULTILATERAL TRADE NEGOTIATIONS: THE LEGAL TEXTS 69, 70 (1995).
133. On the Seattle meeting, see, e.g., Ved Nanda, Battle in Seattle, DENVER POST,
Nov. 30, 1999, at llB.
134. Biosafety Protocol, supra note 2, art. 15; Annex III.
135. Id. art. 16.
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implementing the Protocol, with special attention to the needs of devel-
oping countries. 136 Special provisions address capacity-building of de-
veloping countries, including appropriate scientific and technical train-
ing; risk assessment and risk management for biosafety; and the
enhancement of technological and institutional capacities in biosafety.'
3 7
The importing country may make its decision by taking into account
"socio-economic considerations arising from the impact of living modi-
fied organisms on the conservation and sustainable use of biological di-
versity, especially with regard to the value of biological diversity to in-
digenous and local communities."'3 8 As to liability and redress for
damage resulting from transboundary movements of LMOs, the Proto-
col postpones any decision to the first meeting of the Conference of the
Parties.19 Every five years the parties are to assess the effectiveness of
the Protocol. 40 The Protocol does not allow any reservations. "'
As the Executive Director of the United Nations Environment Pro-
gram, Klaus Topfer, said after the adoption of the Protocol, it "was a
historic event that gave the right signal for future global cooperation." 2
As the first treaty to recognize GMOs as distinctive and apply the pre-
cautionary principle, it certainly is an important step forward in the
development of international environmental law.
V. REGULATION OF GMOs IN EUROPE
A. Introduction
The European Union has undertaken extensive measures to regu-
late GMOs, mainly in response to consumers' concerns with the poten-
tial hazards of GMO foods and crops. In addition, many European
states have unilaterally imposed even more stringent regulations. Four
European laws will be discussed here: Council Directive 90/220/EEC of
April 23, 1990, on the deliberate release of GMOs into the environ-
ment;4 3 Regulation No. 258/97 of January 27, 1997, the Novel Foods
Regulation;' Commission Directive 97/35/EC of June 18, 1997, amend-
ing Annex III of Directive 90/220/EEC, to require the labeling of prod-
136. Id. art. 20(b).
137. Id. art. 22.
138. Id. art. 26.
139. Id. art. 27. The Conference of the Parties is to serve as the meeting of the Parties
to the Biosafety Protocol. Id. art. 29.
140. Id. art. 35.
141. Id. art. 38.
142. See Biosafety Protocol, supra note 2.
143. See generally 1990 O.J. (L 117).
144. See 1997 O.J. (L 43).
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ucts that contain GM~s;45 and Council Regulation No. 1139/98 of May
26, 1998, concerning the compulsory indication of the labeling of certain
foodstuffs produced from GMOs.4 6
B. Council Directive 90/220
In the preamble to Council Directive 90/220, the Council of the
European Communities provided its rationale for prescribing a legal
framework specifically regarding the deliberate release of GMOs: (1) the
need to take preventive action; (2) the potential effects of GMO releases
on the environment which may be irreversible; and (3) the need to ap-
proximate the laws of the member states to ensure that the likely un-
equal conditions of competition or barriers to trade because of disparity
between member states' regulations of products containing GMOs do
not adversely affect the functioning of the Common Market."7 The Di-
rective seeks to provide "a high level of protection throughout the
Community" on health, safety, environmental and consumer protection
and to ensure the safe development of industrial products utilizing
GMOs."4' Thus, the objective of the Directive is to approximate the laws
of the EU member states on the placing into the market of products
containing GMOs that are intended for subsequent release into the en-
vironment.4 9
The Directive obligates each member state to take "appropriate
measures" to avoid adverse effects on human health and the environ-
ment from the deliberate release or placing into the market for the de-
liberate release of GMOs.1' Each member state is to designate the
competent authority responsible for the implementation of the Directive
and to ensure that such authority takes appropriate control measures
for such implementation.1 5' The Directive provides distinct yet similar
norms and procedures regarding the deliberate release of GMOs into
the environment for research and development purposes 152 and for plac-
ing products containing GMOs into the market.'53
145. See Commission Directive 97/35/EC, 1997 O.J. (L 169), June 18, 1997 (it should
be noted that in April 1994, Council Directive 90/200/EEC was amended by Commission
Directive 94/15, 1994 O.J. (L 103), which changed Annex II, "Information Required in the
Notification").
146. Council Regulation (EC) No. 1139/98 of May 26 1998, Concerning the Compulsory
Indication of the Labelling of Certain Foodstuffs Produced From Genetically Modified Or-
ganisms of Particulars Other Than Those Provided For in Directive 79/112/EEC, 1998
O.J. (L 159).
147. See Council Directive 90/220/EEC, 1994, pmbl.
148. Id.
149. 1990 O.J. (L 117), art. 1.
150. Id. art. 4(1).
151. Id. art. 4(2), (3).
152. Id. arts. 5-9.
153. Id. arts. 10-18.
VOL. 28:3
2000 THE BIOSAFETY PROTOCOL AND REGULATIONS IN EUROPE
Before deliberately releasing a GMO for research purposes, the
person proposing such release must notify the competent national au-
thority within the pertinent territory of the risks involved and the con-
ditions and the environment in which the release is to take place."5 The
competent authority must examine the notification, evaluate the risks
and give its written consent as a prerequisite for release.'55 After com-
pletion of a release, the person is to send to the competent authority the
result of such release regarding any risk to human health or the envi-
ronment. 5 ' The competent authorities are to send to the Commission a
summary of each notification, and the Commission in turn is to forward
these summaries to other member states.157 The competent authorities
are to then inform the other member states and the Commission of the
final decision whether the notification is in compliance with this Direc-
tive, thus allowing the release or rejecting the notification in the event
that the release does not fulfill the Directive's conditions.1
8
The procedure is similar for the deliberate release of a commercial
GMO product. The manufacturer or importer of a GMO is to notify the
competent authorities of the member state where the GMO is to be
placed into the market for the first time. 59 The requirements for such
notification are listed in Annex II."6° A risk assessment must be con-
ducted concerning the possible effects on human health and the envi-
ronment. 16' The notifying party must also provide its "Proposal for La-
beling and Packaging." 62 The competent authority of the member state,
after receiving a notification, is required to examine it for compliance
with the Directive, "giving particular attention to the environmental
risk assessment and the recommended precautions related to the safe
use of the product."'6 The competent authority is also required to for-
ward the dossier to the Commission with a favorable opinion, or reject
the proposed release within 90 days of receiving the notification."M A
release requires written consent by the Commission and the other
member states."
The Commission is then to inform the competent authorities in
154. See id. art. 5(1), (2).
155. See id. art. 6.
156. Id. art. 8.
157. Id. art. 9(1) and (2).
158. Id. art. 9(3); pursuant to art. 6(2) conditions.
159. See id. art. 11(1).
160. See id. Annex II.
161. Id. art. 11(1).
162. Id.
163. Id. art. 12(1).
164. Id. art. 12(2).
165. Id. art. 11(5).
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other member states, forwarding the dossier.'" In case of no objection
from any others, the competent authority that received the original no-
tification is to give its consent for the release, informing the Commis-
sion and other member states.1 67 However, if there is any objection from
the competent authority of another state, the Commission is to submit
the proposed measures to a committee composed of the representatives
of the member states and chaired by the representative of the Commis-
sion."' The Commission is to "adopt the measures.., if they are in ac-
cordance with the opinion of the committee." 6 However, if they are not
in accordance with the opinion of the committee or if no opinion is de-
livered, the Commission is to forward the proposal to the Council, which
will decide by a majority vote.7 ° If the Council does not act within a pe-
riod of three months, the Commission is to adopt the proposed meas-
ures.17 1 If the Commission has taken a favorable decision, the compe-
tent authority that had received the notification is to give its written
consent to the placing of the GMO product and is to inform the other
member states and the Commission that it has done so. 72 After such
written consent the GMO product may be used without further notifica-
tion throughout the EU. 73 No member state of the EU is to "prohibit,
restrict or impede the placing on the market of products containing, or
consisting of, GMOs which comply with the requirements of this Direc-
tive ."
The Directive authorizes provisional restrictions by a member state
on the use and/or sale of GMOs in its territory if there are "justifiable
reasons" to consider that such product "constitutes a risk to human
health or the environment." 75 Finally, intellectual property rights re-
lating to the data received are to be protected by the Commission and
the competent authorities are not to divulge to third parties any confi-
dential information notified or exchanged under this Directive.'76
The Commission decisions approving GMO products for release
pursuant to the procedures prescribed under Directive 90/220 have
caused considerable concern and controversy in member states and in
the European Parliament. 17  There have been several attempts to
166. See id. art. 13(1).
167. Id.
168. Id. arts. 13(3), 21.
169. Id. art. 21.
170. Id.
171. See id.
172. Id. art. 13(4).
173. Id. art. 13(5).
174. Id. art. 15.
175. Id. art. 16 (1).
176. Id. art. 19(1).
177. For a discussion of these developments, see Stewart & Johanson, supra note 42, at
259-68.
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strengthen prior prescriptions regarding the release of GMOs and to ex-
tend the scope of European regulations regarding GMOs. A few impor-
tant developments will be noted here.
C. Regulation No. 258/97
On January 27, 1997, the European Union adopted Regulation
Number 258/97. The new regulation applies to GMOs in processed
foods likely to be purchased by consumers. It is aimed at providing a
uniform law for novel foods throughout the European Union. 7 ' The
regulation applies to foods "which have not hitherto been used for hu-
man consumption to a significant degree within the Community, 79 in-
cluding food products containing GMOs within the meaning of the prior
Council Directive 90/220/EEC, food produced by but not containing
GMOs, and foods "with a new or intentionally modified primary molecu-
lar structure. "'"°
The procedure for approval is similar to the one established in the
1990 Council Directive discussed above, insofar as the one seeking to
introduce the novel food into the European Union must submit a re-
quest to the member state in which the product is to be placed into the
market for the first time and also to the Commission. ' The request to
the member state is to specify how the product is to be labeled, 8 2 indi-
cating whether because of the food's characteristics it is no longer
equivalent to an existing food.' Scientific assessment is to determine
whether a food is not equivalent to an existing food, and thus novel."
The purpose is to inform the final consumer through labeling that
GMOs are present in the food or that the food "may contain" GMOs
which is to be labeled as such.' There are detailed provisions regard-
ing the assessment of such food and the role of the Commission to au-
thorize measures proposed by the applicant, 8 6 and also for provisional
restrictions, which may be imposed by a member state if the food poses
risks to human health or the environment.
8 7
178. For the legislative process leading to the adoption of this regulation, see id. at
275-78.
179. Commission Regulation No. 258/97, 1997 O.J. (L 43), art. 1(2).
180. Id. art. 1, paras. (2)(a)-(c).
181. See id. art. 4(1).
182. See id. art. 6(1).
183. See id. art. 8(1)(a).
184. See id.
185. See id. art. 8(1)(d).
186. See id. arts. 6-7, 13.
187. See id. arts. 12-13.
DENV. J. INT'L L. & POLY
D. Commission Directive 97/35/EC8M
After having gained experience with the placing of GMOs into the
market since the issuance of Council Directive of 1990, the Commission
considered it necessary to amend Annex III to that Directive, which
contains the additional information required in the case of notification
for placing GMOs into the market.
This must include in a label or an accompanying document an indi-
cation that the product contains, or consists of genetically modified or-
ganisms. In the case of products to be placed on the market in mixtures
with non-genetically modified organisms, information on the possibility
that the genetically modified organisms may be present, is sufficient. 9
It should be emphasized that the amendment does not require GMO
products and non-GMO products to be segregated.
E. Council Regulation No. 1139/1998190
As the Novel Foods Regulation, which mandates labeling, did not
apply retroactively, the Council adopted a new regulation to apply to
"foods and food ingredients which are to be delivered as such to the fi-
nal consumer.., produced, in whole or in part," from genetically modi-
fied soybeans and genetically modified maize, 19' which had been earlier
authorized under Directive 90/220/EEC. The Council identified as one
of the purposes of the new regulation the necessity to adopt uniform EU
labeling rules for these products"9 because several member states had
unilaterally taken measures on labeling and there was concern that
"differences between those measures [could] impede the free movement
of those foods and food ingredients and thereby adversely affect the
functioning of the internal market."193 The Council also felt it:
necessary to ensure that the final consumer is informed of any charac-
teristics or food property, such as composition, nutritional value or nu-
tritional effects or the intended use of the food, which renders a food or
food ingredients no longer equivalent to an existing food or food ingre-
dient; [and] for that purpose, foods and food ingredients produced from
genetically modified soyabeans or from genetically modified maize
which are not equivalent to conventional counterparts should be sub-
ject to labeling requirements."
It further said that labeling requirements are to be based on scien-
188. 97/35/EC, 1997 O.J. (L 169).
189. Id. Annex III, C.
190. 1998 O.J. (L 159).
191. Id. art. 1(1).
192. Id. pmbl, para. 4.
193. Id.
194. Id. para. 9.
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tific evaluation,'95 and should not be "more burdensome than necessary
but sufficiently detailed to supply consumers with the information they
require. " "9
The regulation is not to apply to "food additives, flavourings for use
in foodstuffs or extraction solvents used in the production of food-
stuffs." 197 The additional specific labeling requirement includes the re-
quirement for the words "produced from genetically modified soya" or
"produced from genetically modified maize," as appropriate.9 8 It is to
appear in the list of ingredients, a footnote to the list, or some other
clear location on the product, where the food consists of more than one
ingredient. Where no list of ingredients exists, the words "produced
from genetically modified soya" or "produced from genetically modified
maize," as appropriate, is to appear clearly on the labeling of the food.' 9
These labeling regulations are minimum requirements and produc-
ers are not precluded from including any additional information about
their products on the label, "such as the absence of foods and food in-
gredients produced from genetically modified soyabeans and maize, or
the presence of such foods and food ingredients in cases where it is not
scientifically verifiable but evidence of it is available through other
means."
2 °0
F. Subsequent Developments
Subsequent to the adoption of this regulation, the Commission an-
nounced in Decision 98/613/EC on October 21, 1998,21 that it intended
to remove the exemption contained in Council Regulation 1139/98 for
food additives and flavorings genetically modified or produced by ge-
netic engineering.
In June 1999, Europe's environment ministers agreed on even
tougher controls on GMOs by introducing new "risk assessment" rules
to monitor scientific evidence and to provide for a clear label that reads:
"This product contains genetically modified organisms," for products
containing more than a certain percentage of GM ingredients, and sub-
stituting a reapproval process for all new GM plants and seeds ap-
proved for sale instead of the currently available permanent consent
195. Id. para. 10.
196. Id. para. 12.
197. Id. art. 1(2).
198. Id. art. 2(3)(a).
199. Id. art. 2(3)(b).
200. Id. pmbl, para. 20.
201. Commission Decision 98/613/EC, concerning a draft Decree of the Republic of
Austria on the identification of genetically modified additives and flavourings used as food
ingredients, 1998 O.J. (L 291).
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mechanism.202
Among other developments, on January 12, 2000, the European Commission pro-
posed the creation of an all-Europe food safety agency, which envisions the crea-
tion of an advisory body of scientists, unlike the US FDA, which is an in-
dependent agency. °3 And in March 2000, the Commission continued its
de facto moratorium on authorizing GM products as it deferred for six
months a decision on two Swede rapes and one fodder beet, although all
these products had been approved as safe by EU scientists."' No new
authorizations have been granted since October 1998 and fourteen ap-
plications are still awaiting approval. 5 However, in July 2000, the
European Union announced that the European Commission was con-
sidering ending the two-year moratorium on licensing GM products af-
ter tighter licensing laws are approved by the EU governments and the
European Parliament, although environmentalists and some govern-
ments are likely to oppose such a plan."2
VI. CONCLUSION
The potential benefits of GM food and food products notwithstand-
ing, the concern with safety has steadily grown and is currently intense
in Europe, although it is also prevalent in many other parts of the
world. The Biosafety Protocol is a promising regulatory step interna-
tionally, but European regulations are more effective.
Perhaps the creation of a new world body to monitor biotechnology
should be seriously considered. Such a proposal, with the proposed
functions of such a body being to monitor the multinationals and advise
governments on consumer safety and ethics, was offered by several
eminent scientists at the Edinburgh conference on GM food safety held
in late February 2000. Sir John Krebs, who chaired the conference,
said
[w]e need industry, regulators, scientists, consumers, and we need to
consider ethics, values and beliefs, issues of world trade, intellectual
property rights, and exploitation of the developing world. By ironing
out these problems and reaching a consensus, then politicians can de-
cide the way forward.0 7
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It is imperative that the world community undertake the regulation
of biotechnology in a coherent and consistent fashion, because the po-
tential risks are enormous and possibly irreversible.

